JP2020531454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531454A5 JP2020531454A5 JP2020508581A JP2020508581A JP2020531454A5 JP 2020531454 A5 JP2020531454 A5 JP 2020531454A5 JP 2020508581 A JP2020508581 A JP 2020508581A JP 2020508581 A JP2020508581 A JP 2020508581A JP 2020531454 A5 JP2020531454 A5 JP 2020531454A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- alkoxy
- methoxy
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 44
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000003545 alkoxy group Chemical group 0.000 claims 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 20
- -1 alkyl-methoxy Chemical group 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 229910052736 halogen Inorganic materials 0.000 claims 16
- 150000002367 halogens Chemical class 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 16
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 15
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 15
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 230000004064 dysfunction Effects 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 8
- 102100038354 Metabotropic glutamate receptor 4 Human genes 0.000 claims 7
- 230000000694 effects Effects 0.000 claims 7
- 108010038422 metabotropic glutamate receptor 4 Proteins 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- 201000000980 schizophrenia Diseases 0.000 claims 6
- 208000019901 Anxiety disease Diseases 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 208000020016 psychiatric disease Diseases 0.000 claims 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 4
- 208000020925 Bipolar disease Diseases 0.000 claims 4
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000005062 synaptic transmission Effects 0.000 claims 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 4
- 208000019022 Mood disease Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 230000036506 anxiety Effects 0.000 claims 3
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 claims 2
- GPBBNPPLBQIADY-UHFFFAOYSA-N 4,4-dimethyloxane Chemical compound CC1(C)CCOCC1 GPBBNPPLBQIADY-UHFFFAOYSA-N 0.000 claims 2
- 206010012218 Delirium Diseases 0.000 claims 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 2
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 claims 2
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 206010027175 memory impairment Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 238000001228 spectrum Methods 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000018460 Feeding disease Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000000172 Medulloblastoma Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000013404 behavioral symptom Diseases 0.000 claims 1
- 230000033026 cell fate determination Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001066 destructive effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000001272 neurogenic effect Effects 0.000 claims 1
- 230000006576 neuronal survival Effects 0.000 claims 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 claims 1
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- STHBHEYNLYNJAM-UHFFFAOYSA-N Cc1n[nH]c2c1cccn2 Chemical compound Cc1n[nH]c2c1cccn2 STHBHEYNLYNJAM-UHFFFAOYSA-N 0.000 description 1
- JJLBTVYCYWUHCH-UHFFFAOYSA-N Cc1n[nH]c2c1nccc2 Chemical compound Cc1n[nH]c2c1nccc2 JJLBTVYCYWUHCH-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546290P | 2017-08-16 | 2017-08-16 | |
| US62/546,290 | 2017-08-16 | ||
| PCT/US2018/046801 WO2019036534A1 (en) | 2017-08-16 | 2018-08-16 | INDAZOLE COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIALIZERS, COMPOSITIONS, AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTIONS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531454A JP2020531454A (ja) | 2020-11-05 |
| JP2020531454A5 true JP2020531454A5 (https=) | 2021-09-16 |
| JP7253832B2 JP7253832B2 (ja) | 2023-04-07 |
Family
ID=63579734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508581A Active JP7253832B2 (ja) | 2017-08-16 | 2018-08-16 | ｍＧＬｕＲ４アロステリック増強剤としてのインダゾール化合物、組成物、および神経機能不全を治療する方法 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US11427573B2 (https=) |
| EP (1) | EP3668865A1 (https=) |
| JP (1) | JP7253832B2 (https=) |
| KR (1) | KR102687118B1 (https=) |
| CN (1) | CN111225913B (https=) |
| AU (1) | AU2018317403B2 (https=) |
| BR (1) | BR112020003292A2 (https=) |
| CA (1) | CA3072493A1 (https=) |
| CL (1) | CL2020000360A1 (https=) |
| CO (1) | CO2020002576A2 (https=) |
| EA (1) | EA202090467A1 (https=) |
| IL (1) | IL272575B2 (https=) |
| PE (1) | PE20200756A1 (https=) |
| SG (1) | SG11202001264UA (https=) |
| UA (1) | UA128084C2 (https=) |
| WO (1) | WO2019036534A1 (https=) |
| ZA (1) | ZA202001321B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2019006157A1 (en) | 2017-06-28 | 2019-01-03 | Vanderbilt University | Pyridine quinoline compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2020311940A1 (en) | 2019-07-11 | 2022-02-03 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| WO2023114224A1 (en) | 2021-12-13 | 2023-06-22 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| JP2025540259A (ja) * | 2022-12-08 | 2025-12-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規置換ピラジン－カルボキサミド－イミダゾピリジン誘導体 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2668811A1 (en) * | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| US20080153810A1 (en) | 2006-11-15 | 2008-06-26 | Forest Laboratories Holdings Limited | Indazole derivatives useful as melanin concentrating receptor ligands |
| MX2009006401A (es) | 2006-12-20 | 2009-06-23 | Nerviano Medical Sciences Srl | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. |
| GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
| AU2010208176A1 (en) | 2009-01-28 | 2011-09-15 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2456310A4 (en) | 2009-07-23 | 2013-01-23 | Univ Vanderbilt | SUBSTITUTED BENZOIMIDAZOLSULFONAMIDES AND SUBSTITUTED INDOLSULFONAMIDES AS MGLUR4 POTENTIATORS |
| RU2012114770A (ru) | 2009-09-04 | 2013-10-10 | Вандербилт Юниверсити | АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ |
| JP2013508413A (ja) | 2009-10-22 | 2013-03-07 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤、組成物、および神経機能不全を治療する方法 |
| KR20120115252A (ko) | 2009-11-06 | 2012-10-17 | 벤더르빌트 유니버시티 | Ｍｇｌｕｒ4 알로스테릭 강화제로서 아릴 및 헤테로아릴 설폰, 조성물 및 신경 기능이상을 치료하는 방법 |
| US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| EP2533639A4 (en) | 2010-02-11 | 2013-08-21 | Univ Vanderbilt | PYRAZOLOPYRIDIN, PYRAZOLOPYRZIN, PYRAZOLOPYRIMIDIN, PYRAZOLOTHIOPHEN AND PYRAZOLOTHIAZOL COMPOUNDS AS ALLOSTERIC MGLUR4 POTENTRANS AND COMPOUNDS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| MX2012009377A (es) | 2010-02-11 | 2012-09-12 | Univ Vanderbilt | Benzotiazoles y azabenzotiazoles como potenciadores alostericos mglur4, composiciones y metodos para tratar la disfuncion neurologica. |
| EP2568809A4 (en) | 2010-05-12 | 2013-11-06 | Univ Vanderbilt | HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| CN106535890A (zh) | 2014-03-20 | 2017-03-22 | 萨穆梅德有限公司 | 5‑取代的吲唑‑3‑羧酰胺及其制备和应用 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016115282A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzoisoxazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10227343B2 (en) | 2015-01-30 | 2019-03-12 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US10968227B2 (en) | 2016-11-08 | 2021-04-06 | Vanderbilt University | Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US11427573B2 (en) | 2017-08-16 | 2022-08-30 | Vanderbilt University | Indazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
-
2018
- 2018-08-16 US US16/639,539 patent/US11427573B2/en active Active
- 2018-08-16 JP JP2020508581A patent/JP7253832B2/ja active Active
- 2018-08-16 PE PE2020000257A patent/PE20200756A1/es unknown
- 2018-08-16 CA CA3072493A patent/CA3072493A1/en active Pending
- 2018-08-16 UA UAA202001405A patent/UA128084C2/uk unknown
- 2018-08-16 IL IL272575A patent/IL272575B2/en unknown
- 2018-08-16 CN CN201880067616.7A patent/CN111225913B/zh active Active
- 2018-08-16 BR BR112020003292-1A patent/BR112020003292A2/pt active IP Right Grant
- 2018-08-16 EP EP18769523.4A patent/EP3668865A1/en active Pending
- 2018-08-16 KR KR1020207007596A patent/KR102687118B1/ko active Active
- 2018-08-16 US US16/104,011 patent/US10508105B2/en active Active
- 2018-08-16 EA EA202090467A patent/EA202090467A1/ru unknown
- 2018-08-16 SG SG11202001264UA patent/SG11202001264UA/en unknown
- 2018-08-16 AU AU2018317403A patent/AU2018317403B2/en active Active
- 2018-08-16 WO PCT/US2018/046801 patent/WO2019036534A1/en not_active Ceased
-
2020
- 2020-02-12 CL CL2020000360A patent/CL2020000360A1/es unknown
- 2020-02-28 ZA ZA2020/01321A patent/ZA202001321B/en unknown
- 2020-03-04 CO CONC2020/0002576A patent/CO2020002576A2/es unknown
-
2022
- 2022-04-26 US US17/730,112 patent/US12291521B2/en active Active
-
2025
- 2025-05-06 US US19/200,356 patent/US20260070897A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531454A5 (https=) | ||
| JP2013526544A5 (https=) | ||
| ES2923875T3 (es) | Moduladores de la vía integrada del estrés | |
| KR102566924B1 (ko) | 케모카인 수용체 조절제 및 이의 용도 | |
| AU2018360854B2 (en) | Modulators of the integrated stress pathway | |
| CN105492439B (zh) | 作为溴结构域抑制剂的取代的双环化合物 | |
| CN100351251C (zh) | 吲哚基马来酰亚胺衍生物 | |
| US10208034B2 (en) | Quinoline derivative | |
| JP5714030B2 (ja) | Ｃ−Ｍｅｔ阻害剤としてのイミダゾ［１，２−ｂ］［１，２，４］トリアジン | |
| TWI781935B (zh) | 經取代之吲唑於治療及預防動物之疾病之用途 | |
| AU2023201399A1 (en) | Modulators of the integrated stress pathway | |
| JP2019142941A (ja) | ＰＩ３Ｋδ関連障害治療のためのピラゾロピリミジン誘導体の使用 | |
| US20210363136A1 (en) | Modulators of the integrated stress pathway | |
| TW201808914A (zh) | 整合應激途徑之調節劑 | |
| JP2019031560A5 (https=) | ||
| JP2009542610A5 (https=) | ||
| JP2011515482A5 (https=) | ||
| JP2014503567A5 (https=) | ||
| JP2014533284A5 (https=) | ||
| WO2017001853A1 (en) | Antiviral compounds | |
| JPWO2005035516A1 (ja) | 新規縮合複素環化合物およびその用途 | |
| JP2010523722A5 (https=) | ||
| JP2015535252A5 (https=) | ||
| JP2010534647A5 (https=) | ||
| JPWO2004101529A1 (ja) | 含窒素複素環化合物およびその医薬用途 |